机构

• 金属研究所 [2]
• 上海药物研究所 [1]
• 合肥物质科学研究院 [1]

采集方式

• OAI收割 [4]

内容类型

• 期刊论文 [4]

发表日期

• 2021 [1]
• 2020 [1]
• 2017 [2]

学科主题

筛选

浏览/检索结果: 共4条，第1-4条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文  OAI收割 THORACIC CANCER, 2021, 页码: 9 作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu   |  收藏  |  浏览/下载：66/0  |  提交时间：2021/05/24 EGFR‐  mutant non‐  small cell lung cancer  famitinib  HS‐  10296  multi‐  targeted tyrosine kinase inhibitor  third‐  generation EGFR inhibitor   Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report 期刊论文  OAI收割 FRONTIERS IN ONCOLOGY, 2020, 卷号: 10 作者:  Yang, Zi-yan;  Huang, Jia-huan;  Chen, Bo;  Xu, Chun-wei;  Lei, Lei   |  收藏  |  浏览/下载：60/0  |  提交时间：2020/11/30 salivary duct carcinoma  tyrosine kinase inhibitor  pyrotinib  HER2 positive  targeted   Design, Synthesis and Biological Activities of N-(Furan-2-ylmethyl)-1H-indole-3-carboxamide Derivatives as Epidemal Growth Factor Receptor Inhibitors and Anticancer Agents 期刊论文  OAI收割 CHEMICAL RESEARCH IN CHINESE UNIVERSITIES, 2017, 卷号: 33, 期号: 3, 页码: 365-372 作者:  Zhang Lan;  Deng Xinshan;  Wu Jiaofeng;  Meng Guangpeng;  Liu Congchong   |  收藏  |  浏览/下载：62/0  |  提交时间：2021/02/02 MOLECULAR TARGETED DRUGS  TYROSINE KINASE  CANCER-CELLS  EGFR  RESISTANCE  POTENT  DISCOVERY  NSCLC  Anticancer activity  Epidemal growth factor receptor(EGFR) inhibitor  N-( Furan-2-ylmethyl)-1H-indole3-carboxamide derivative   Design, Synthesis and Biological Activities of N-(Furan-2-ylmethyl)-1H-indole-3-carboxamide Derivatives as Epidemal Growth Factor Receptor Inhibitors and Anticancer Agents 期刊论文  OAI收割 CHEMICAL RESEARCH IN CHINESE UNIVERSITIES, 2017, 卷号: 33, 期号: 3, 页码: 365-372 作者:  Zhang Lan;  Deng Xinshan;  Wu Jiaofeng;  Meng Guangpeng;  Liu Congchong   |  收藏  |  浏览/下载：59/0  |  提交时间：2021/02/02 MOLECULAR TARGETED DRUGS  TYROSINE KINASE  CANCER-CELLS  EGFR  RESISTANCE  POTENT  DISCOVERY  NSCLC  Anticancer activity  Epidemal growth factor receptor(EGFR) inhibitor  N-( Furan-2-ylmethyl)-1H-indole3-carboxamide derivative